TearSolutions: Naturally Treating Dry Eye (225)
Tear Solutions

TearSolutions’ lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). 

The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.



Recent Posts

Lessons Learned – Medical Device

What Not To Do We can learn from our wins, but it’s often the things…

JP Morgan Week 2023

For most startups and investors in the healthcare industry, the week of JP Morgan’s Healthcare…

Raising Early Stage Capital

While we have covered aspects of this topic in almost 100 blog articles over the…